<SEC-DOCUMENT>0001104659-20-082309.txt : 20200709
<SEC-HEADER>0001104659-20-082309.hdr.sgml : 20200709
<ACCEPTANCE-DATETIME>20200709123630
ACCESSION NUMBER:		0001104659-20-082309
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20200708
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200709
DATE AS OF CHANGE:		20200709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEALTHEQUITY, INC.
		CENTRAL INDEX KEY:			0001428336
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36568
		FILM NUMBER:		201020050

	BUSINESS ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020
		BUSINESS PHONE:		801-727-1000

	MAIL ADDRESS:	
		STREET 1:		15 WEST SCENIC POINTE DRIVE
		STREET 2:		SUITE 100
		CITY:			DRAPER
		STATE:			UT
		ZIP:			84020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHEQUITY INC
		DATE OF NAME CHANGE:	20080227
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2024096d4_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:hqy="http://healthequity.com/20200708">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_hqy_healthequity.com_20200708 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20200708_20200708_zoJRkzlRpN8l -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001428336 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityCentralIndexKey">0001428336</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="hqy-20200708.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-07-08to2020-07-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001428336</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-08</xbrli:startDate>
        <xbrli:endDate>2020-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form&#160;<span id="xdx_903_edei--DocumentType_c20200708__20200708_zOsPvXw2lR77"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)&#160;of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--DocumentPeriodEndDate_c20200708__20200708_zxggvLiBs59k"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 8, 2020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number<b>: <span id="xdx_909_edei--EntityFileNumber_c20200708__20200708_z3VMmXUtK1il"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityFileNumber">001-36568</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20200708__20200708_zwScgQ3glKL6"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityRegistrantName">HEALTHEQUITY,&#160;INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20200708__20200708_zTbZIHzzX3F3"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_906_edei--EntityFileNumber_c20200708__20200708_zX7skn56QKsg"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityFileNumber">001-36568</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20200708__20200708_zFwtKaGeiQZ4"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityTaxIdentificationNumber">52-2383166</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br /> incorporation or organization)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br />
File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br /> Identification Number)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20200708__20200708_z6yyQl61fOF1"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityAddressAddressLine1">15 West Scenic Pointe Drive</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine2_c20200708__20200708_z9KrAeHUJCV2"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityAddressAddressLine2">Suite&#160;100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20200708__20200708_zNP45tc5ek88"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityAddressCityOrTown">Draper</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20200708__20200708_zt9VMEEyzSjg"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20200708__20200708_zE9qpVCZWwvc"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:EntityAddressPostalZipCode">84020</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_902_edei--CityAreaCode_c20200708__20200708_z4qY3BVmPjK6"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:CityAreaCode">801</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20200708__20200708_zi4wWwDCAA3h"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:LocalPhoneNumber">727-1000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including Zip Code, and Telephone
Number, including Area Code, of Registrant&#146;s Principal Executive Offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&#160;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90E_edei--WrittenCommunications_c20200708__20200708_z6BswtPSYRN4"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities
Act (17 CFR 230.425)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20200708__20200708_znf4D52A7eGa"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange
Act (17 CFR 240.14a-12)</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20200708__20200708_zhkeKE3bs926"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20200708__20200708_z2Gv9UK55Tli"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17
CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20200708__20200708_zSjadklRQqId"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 37%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title&#160;of&#160;each&#160;class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 26%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading&#160;Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--Security12bTitle_c20200708__20200708_zxNYrMGiPWa2"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:Security12bTitle">Common stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--TradingSymbol_c20200708__20200708_zUdJhIonGNA9"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" name="dei:TradingSymbol">HQY</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SecurityExchangeName_c20200708__20200708_zeuyltSLdJo6"><ix:nonNumeric contextRef="From2020-07-08to2020-07-08" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item 1.01</b></span></td><td style="width: 90%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry into a Definitive Material Agreement</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July&#160;8, 2020, HealthEquity,&#160;Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
entered into an underwriting agreement (the &#8220;<span style="text-decoration: underline">Underwriting Agreement</span>&#8221;) with Wells Fargo Securities, LLC, J.P.
Morgan Securities LLC and the other several underwriters named therein (the &#8220;<span style="text-decoration: underline">Underwriters</span>&#8221;). Pursuant to the
terms of the Underwriting Agreement, the Company agreed to sell, and the Underwriters agreed to purchase, subject to and on the
conditions set forth therein, an aggregate of 4,600,000 shares of the Company&#8217;s common stock. The Company has also granted
the Underwriters an option to purchase up to an additional 690,000 shares of the Company&#8217;s common stock. The Company estimates
that the net proceeds from the offering will be approximately $249.5 million, or approximately $287 million if the Underwriters
exercise in full their option to purchase additional shares of the Company&#8217;s common stock after deducting the estimated discount
to the Underwriters and the related fees and expenses of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement contains customary representations,
warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters,
including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering is being made pursuant to the Company&#8217;s effective
shelf registration statement on Form&#160;S-3 (Registration No.&#160;333-227231), including the prospectus dated September&#160;7,
2018 as supplemented by the prospectus supplement dated July&#160;8, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Underwriting Agreement is filed as Exhibit&#160;1.1 to this
Current Report on Form&#160;8-K and incorporated herein by reference. The above description is qualified in its entirety by reference
to such exhibit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: bottom">
    <td style="width: 10%; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item 9.01</b></span></td>
    <td style="width: 90%; padding-left: 10pt; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit&#160;No.</b></span></td>
    <td style="padding-bottom: 1pt; width: 3%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 87%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><a href="tm2024096d4_ex1-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2024096d4_ex1-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Underwriting Agreement, dated as of July&#160;8, 2020, by and among HealthEquity,&#160;Inc., Wells Fargo Securities, LLC, J.P. Morgan Securities LLC and the other several underwriters named therein.</span></a></td></tr>
<tr style="vertical-align: top">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>HEALTHEQUITY,&#160;INC.</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 6%"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 44%">/s/ Darcy Mott</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Darcy Mott</span></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President and Chief Financial Officer</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: July&#160;9, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LppWRO2jRUWsIkXE19huJdhmyyb+HclbGlvEZWFZZr4ZIUKxoqWukeE0zzM4YNPWyiHkWCGjKdA70vUmAX9zvGjrWBnXvT8wJc+gZ8YDeS680Fnv2mKZgJwMR9EwmoGcJnEM+60IvnpKptIlGqdVDcqUsGdqWaNT/OoTDupJhppXV3VEtppMAtFA9vIbYhnFsKO7ehBfLWRZKoKwm0CsmG7tt+ZmHTWwqLHxXbZH/xt8AD1TSYE= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2024096d4_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Version</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HEALTHEQUITY,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4,600,000 Shares of Common Stock, par
value $0.0001 per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underwriting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">July&nbsp;8, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wells Fargo Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
As Representatives of the<BR>
several Underwriters listed<BR>
in Schedule&nbsp;1 hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Wells Fargo Securities, LLC<BR>
500 West 33<SUP>rd</SUP> Street<BR>
New York, New York 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o J.P. Morgan Securities LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HealthEquity,&nbsp;Inc., a Delaware corporation
(the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several underwriters listed in Schedule&nbsp;1 hereto (the
 &ldquo;<B>Underwriters</B>&rdquo;), for whom you are acting as representatives (the &ldquo;<B>Representatives</B>&rdquo;), an
aggregate of 4,600,000 shares of common stock, par value $0.0001 per share (&ldquo;<B>Common Stock</B>&rdquo;), of the Company
(the &ldquo;<B>Underwritten Shares</B>&rdquo;) and, at the option of the Underwriters, up to an additional 690,000 shares of Common
Stock of the Company (the &ldquo;<B>Option Shares</B>&rdquo;). The Underwritten Shares and the Option Shares are herein referred
to as the &ldquo;<B>Shares</B>&rdquo;. The shares of Common Stock of the Company to be outstanding after giving effect to the
issuance and sale of the Shares are referred to herein as the &ldquo;<B>Stock</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby confirms its agreement
with the several Underwriters concerning the purchase and sale of the Shares, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration
Statement</U>. The Company has prepared and filed with
the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) under the Securities Act of 1933, as amended, and
the rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;<B>Securities Act</B>&rdquo;), an automatic
shelf registration statement, as defined in Rule&nbsp;405 under the Securities Act, on Form&nbsp;S-3 (File No.&nbsp;333-227231),
including a related base prospectus dated September&nbsp;7, 2018 (the &ldquo;<B>Base Prospectus</B>&rdquo;), relating to certain
securities, including the Common Stock and other securities that may be sold from time to time by the Company in accordance with
Rule&nbsp;415 of the Securities Act, and such amendments thereof as may have been required to the date of this Agreement. The
term &ldquo;Registration Statement&rdquo; as used in this Agreement means the initial registration statement (including all exhibits,
financial schedules and all documents and information deemed to be a part of the registration statement by incorporation by reference
or otherwise, including pursuant to Rule&nbsp;430B under the Securities Act), as amended at the time it became effective and as
supplemented or amended, including the information, if any, included or incorporated by reference in any preliminary prospectus
or the final prospectus filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;and Rule&nbsp;430B under the Securities Act.
If the Company has filed an abbreviated registration statement pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act (the
 &ldquo;<B>Rule&nbsp;462 Registration Statement</B>&rdquo;), then any reference herein to the term &ldquo;Registration Statement&rdquo;
shall be deemed to include such Rule&nbsp;462 Registration Statement. The term &ldquo;Preliminary Prospectus&rdquo; as used in
this Agreement means the Base Prospectus and any preliminary prospectus supplement used or filed with the Commission pursuant
to Rule&nbsp;424, in the form provided to the Underwriters by the Company for use in connection with the offering of the Shares.
The term &ldquo;Prospectus&rdquo; means the Base Prospectus, any Preliminary Prospectus and any amendments or further supplements
to such prospectus, and including, without limitation, the final prospectus supplement (the &ldquo;<B>Prospectus Supplement</B>&rdquo;)
filed pursuant to and within the time limits described in Rule&nbsp;424(b)&nbsp;with the Commission in connection with the proposed
issuance and sale of the Shares contemplated by this Agreement. Any reference in this underwriting agreement (this &ldquo;<B>Agreement</B>&rdquo;)
to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents
incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3 under the Securities Act, as of the effective date of the
Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to
 &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement, any Preliminary
Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities
Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;<B>Exchange
Act</B>&rdquo;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have
the meanings given to such terms in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the Applicable Time (as
defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex
A, the &ldquo;<B>Pricing Disclosure Package</B>&rdquo;): a Preliminary Prospectus dated July&nbsp;8, 2020, a Prospectus dated
July&nbsp;8, 2020 and each &ldquo;free-writing prospectus&rdquo; (as defined pursuant to Rule&nbsp;405 under the Securities Act)
listed on Annex A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Applicable Time</B>&rdquo; means
5:45 P.M., New York City time, on July&nbsp;8, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Purchase
of the Shares by the Underwriters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this Agreement, and each Underwriter,
on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein,
agrees, severally and not jointly, to purchase from the Company the respective number of Underwritten Shares set forth opposite
such Underwriter&rsquo;s name in Schedule 1 hereto at a purchase price per Share of $54.32 (the &ldquo;<B>Purchase Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the Company agrees to issue
and sell the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the
representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option
to purchase, severally and not jointly, from the Company up to 690,000 Option Shares at the Purchase Price less an amount per
share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on
the Option Shares. If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall
be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number
of Underwritten Shares set forth opposite the name of such Underwriter in Schedule&nbsp;1 hereto (or such number increased as
set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by
the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their
sole discretion shall make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Underwriters may exercise the option
to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date
of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number
of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and
paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing
Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date
are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business
days prior to the date and time of delivery specified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company understands that the Underwriters intend to make a public offering of the Shares as soon after the effectiveness of this
Agreement as in the judgment of the Representatives is advisable, and initially to offer the Shares on the terms set forth in
the Prospectus. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate
of an Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
for the Shares shall be made by wire transfer in immediately available funds to the accounts specified by the Company to the Representatives
in the case of the Underwritten Shares, at the offices of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, at 885
Third Avenue, New York, New York 10022, at 9:00 A.M., New York City time, on July&nbsp;13, 2020, or at such other time or place
on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree
upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in
the written notice of the Underwriters&rsquo; election to purchase such Option Shares. The time and date of such payment for the
Underwritten Shares is referred to herein as the &ldquo;<B>Closing Date</B>&rdquo;, and the time and date for such payment for
the Option Shares, if other than the Closing Date, is herein referred to as the &ldquo;<B>Additional Closing Date</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the
Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the issuance and sale of such
Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company unless
the Representatives shall otherwise instruct. The certificates for the Shares, if any, will be made available for inspection and
packaging by the Representatives at the office of DTC or its designated custodian not later than 1:00 P.M., New York City time,
on the business day prior to the Closing Date or the Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arm&rsquo;s length contractual counterparty
to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms
of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally,
neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and
the Underwriters shall have no responsibility or liability to the Company with respect thereto. Any review by the Underwriters
of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for
the benefit of the Underwriters and shall not be on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations
and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Preliminary
Prospectus. </I>No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and
each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material
respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes
no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for
use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Pricing
Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of
the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation and warranty with respect
to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished
to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package,
it being understood and agreed that the only such information furnished by any Underwriter consists of the information described
as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer
Free Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company
(including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, used, authorized,
approved or referred to and will not prepare, use, authorize, approve or refer to any &ldquo;written communication&rdquo; (as
defined in Rule&nbsp;405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares
(each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below)
an &ldquo;<B>Issuer Free Writing Prospectus</B>&rdquo;) other than (i)&nbsp;any document not constituting a prospectus pursuant
to Section&nbsp;2(a)(10)(a)&nbsp;of the Securities Act or Rule&nbsp;134 under the Securities Act or (ii)&nbsp;the documents listed
on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives.
Each such Issuer Free Writing Prospectus complied in all material respects with the Securities Act, has been or will be (within
the time period specified in Rule&nbsp;433) filed in accordance with the Securities Act (to the extent required thereby) and does
not conflict with the information included or incorporated by reference in the Registration Statement or the Pricing Disclosure
Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer
Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation
and warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus
in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter
through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood
and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.
Each such Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the public
offer and sale of the Shares or until any earlier date that the Company notified or notifies the Representatives as described
in Section&nbsp;4(d), did not, does not and will not include any information that conflicted, conflicts or will conflict with
the information included or incorporated by reference in the Registration Statement or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration
Statement and Prospectus. </I>The Registration Statement is an &ldquo;automatic shelf registration statement&rdquo; as defined
under Rule&nbsp;405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date
hereof; and no notice of objection of the Commission to the use of such registration statement or any post-effective amendment
thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act has been received by the Company. No order suspending the
effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant
to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to
the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement
and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply
in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading;
and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional
Closing Date, as the case may be, the Prospectus complied and will comply in all material respects with the Securities Act and
will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided
</U>that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and
in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it
being understood and agreed that the only such information furnished by any Underwriter consists of the information described
as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Incorporated
Documents. </I>The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure
Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act,
and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents
so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such
documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein necessary to
make the statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Financial
Statements. </I>The historical financial statements (including the related notes thereto) of the Company and its consolidated
subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and
present fairly in all material respects the historical financial position of the Company and its consolidated subsidiaries as
of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such
historical financial statements have been prepared in conformity with generally accepted accounting principles in the United States
(&ldquo;<B>GAAP</B>&rdquo;) applied on a consistent basis throughout the periods covered thereby, except in the case of unaudited,
interim historical financial statements subject to normal year-end adjustments and which do not contain certain footnotes as permitted
by the applicable rules&nbsp;of the Commission, and any supporting schedules included or incorporated by reference in the Registration
Statement present fairly the information required to be stated therein; and the other historical financial information of the
Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material
respects the information shown thereby; and any pro forma financial information and related notes thereto included or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus (i)&nbsp;have been prepared in accordance
with Article&nbsp;11 of Regulation S-X with respect to <U>pro</U> <U>forma</U> financial statements and (ii)&nbsp;have been properly
presented on the bases described therein; the assumptions underlying such <U>pro</U> <U>forma</U> financial information included in the
Registration Statement, the Pricing Disclosure Package and the Prospectus are a reasonable basis for presenting the effects attributable
to the transactions and circumstances referred to therein and the adjustments used therein are appropriate to give effect to the
transactions or circumstances referred to therein. All &ldquo;non-GAAP financial measures&rdquo; (as such term is defined in the
rules&nbsp;and regulations of the Commission) included or incorporated by reference in the Registration Statement, the Pricing
Disclosure Package and the Prospectus comply with Regulation G under the Exchange Act and Item 10 of Regulation S-K under the
Securities Act, to the extent applicable, in all material respects. To the Company&rsquo;s knowledge, the financial statements
of WageWorks,&nbsp;Inc. (including the related notes thereto) and its consolidated subsidiaries included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus present fairly in all material respects the consolidated
financial position of WageWorks,&nbsp;Inc. and its consolidated subsidiaries as of the dates indicated and the consolidated results
of their operations for the periods specified; and, except as stated therein, to the Company&rsquo;s knowledge, such financial
statements have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Material Adverse Change. </I>Since the date of the most recent financial statements of the Company included or incorporated by
reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change
in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described
as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement,
the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries,
or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital
stock, or any material adverse change, or any development that could reasonably be expected to result in a material adverse change
in, or affecting the business, properties, management, financial position, stockholders&rsquo; equity, results of operations or
prospects of the Company and its subsidiaries taken as a whole;(ii)&nbsp;neither the Company nor any of its subsidiaries has entered
into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its
subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and
its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference
with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion,
flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or
decree of any court or arbitrator or governmental or regulatory authority, except in each case of (i), (ii)&nbsp;and (iii)&nbsp;above,
as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Organization
and Good Standing. </I>The Company and each of its &ldquo;significant subsidiaries&rdquo; (as such term is defined in Rule&nbsp;1-02
of Regulation S-X) have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions
of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership
or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority
necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the
failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have
a material adverse effect on the business, properties, management, financial position, stockholders&rsquo; equity or results of
operations of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under
this Agreement (a &ldquo;<B>Material Adverse Effect</B>&rdquo;). The Company does not own or control, directly or indirectly,
any corporation, association or other entity other than the subsidiaries listed in Exhibit&nbsp;21 to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Capitalization.
</I>The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus under the heading &ldquo;Capitalization&rdquo; and &ldquo;Description of Capital Stock&rdquo;; all the outstanding
shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and non-assessable
and are not subject to any pre-emptive or similar rights that have not been duly waived or satisfied; except as described in or
expressly contemplated by the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without
limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares
of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding
or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible
or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material
respects to the description thereof included or incorporated by reference in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned,
directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except,
in the case of any foreign subsidiary, for directors&rsquo; qualifying shares) and are owned directly or indirectly by the Company,
free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any
third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock
Options. </I>With respect to the outstanding stock options (the &ldquo;<B>Stock Options</B>&rdquo;) granted pursuant to the stock-based
compensation plans of the Company and its subsidiaries (the &ldquo;<B>Company Stock Plans</B>&rdquo;), (i)&nbsp;other than Stock
Options granted under the Company&rsquo;s 2003 Stock Plan and 2005 Stock Plan, each Stock Option intended to qualify as an &ldquo;incentive
stock option&rdquo; under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;) so
qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock
Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of
directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the
necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered
by each party thereto, and (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange
Act and all other applicable laws and regulatory rules&nbsp;or requirements, including the rules&nbsp;of the Nasdaq Global Select
Market (the &ldquo;<B>Nasdaq</B>&rdquo;). Each Company Stock Plan is accurately described in all material respects in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. The Company has not knowingly granted, and there is no and has been
no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options
with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results
of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Due
Authorization. </I>The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations
hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement
and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Underwriting
Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The
Securities</I>. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company, and when issued
and delivered and paid for as described herein, will be duly and validly issued and will be fully paid and non-assessable and
will conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Violation or Default. </I>Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or by-laws or
similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both,
would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a
party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or
any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule&nbsp;or regulation
of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its subsidiaries,
except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such default or violation that would not, individually
or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares by
the Company pursuant to this Agreement and the consummation of the transactions contemplated by this Agreement do not and will
not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under,
or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of
its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the property or assets of the Company, or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions
of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in
the violation by the Company or any of its subsidiaries of any law or statute or any judgment, order, rule&nbsp;or regulation
of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii)&nbsp;above,
for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Consents Required. </I>No consent, filing, approval, authorization, order, license, registration or qualification of or with any
court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company
of this Agreement, the issuance and sale of the Shares by the Company pursuant to this Agreement and the consummation of the transactions
contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals,
authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;<B>FINRA</B>&rdquo;) or the Nasdaq and under applicable state securities laws in connection with the purchase and distribution
of the Shares by the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Legal
Proceedings. </I>Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are
no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its
subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject
that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect; to the knowledge of the
Company, no such investigations, actions, suits or proceedings are threatened, or contemplated by any governmental or regulatory
authority or threatened by others; and (i)&nbsp;there are no current or pending legal, governmental or regulatory actions, suits
or proceedings that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure
Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to
be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Independent
Accountants</I>. (i)&nbsp;PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company and its subsidiaries
is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules&nbsp;and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the
Securities Act and (ii)&nbsp;to the knowledge of the Company, BDO USA, LLP, who has certified certain financial statements of
WageWorks,&nbsp;Inc. and its subsidiaries was previously an independent registered public accounting firm with respect to WageWorks,&nbsp;Inc.
and its subsidiaries within the applicable rules&nbsp;and regulations adopted by the Commission and the Public Company Accounting
Oversight Board (United States) and as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Title
to Real and Personal Property</I>. The Company and its subsidiaries have good and marketable title in fee simple (in the case
of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and
assets that are material to the respective businesses of the Company and its subsidiaries, taken as a whole, in each case free
and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;could not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Title
to Intellectual Property</I>. Except as could not reasonably be expected to have a Material Adverse Effect or as disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries own or possess
adequate rights to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service
mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary
or confidential information, systems or procedures) necessary for the conduct of their respective businesses as currently conducted
and as proposed to be conducted, and the conduct of their respective businesses will not conflict in any material respect with
any such rights of others. The Company and its subsidiaries have not received any written notice of any claim of infringement,
misappropriation or conflict with any such rights of others in connection with its patents, patent rights, licenses, inventions,
trademarks, service marks, trade names, copyrights and know-how, which could reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Cybersecurity;
Data Protection</I>. The Company&rsquo;s and its subsidiaries&rsquo; information technology assets and equipment, computers, systems,
networks, hardware, software, websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are reasonably
believed by the Company to be adequate in all material respects for, and operate and perform in all material respects as required
in connection with, the operation of the business of the Company and its subsidiaries as currently conducted and, to the Company&rsquo;s
knowledge, are free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security
of all IT Systems and data reasonably consistent with industry standards and practices, or as required by applicable regulatory
standards (and including all personal, personally identifiable, sensitive, confidential or regulated data) (&ldquo;<B>IT Data</B>&rdquo;)
and, to the knowledge of the Company there have been no material breaches, violations, outages or unauthorized uses of or accesses
to same, except for those that have been remedied without material cost or liability. The Company and its subsidiaries are presently
in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator
or governmental or regulatory authority and internal policies and contractual obligations relating to the privacy and security
of IT Systems and IT Data and to the protection of such IT Systems and IT Data from unauthorized use, access, misappropriation
or modification, except for such failures as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Data
Privacy and Security Laws</I>. Except as could not reasonably be expected to have a Material Adverse Effect or as disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries are, and since
the Company&rsquo;s inception have been, in compliance with all applicable state and federal data privacy and security laws and
regulations, including without limitation the Health Insurance Portability and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;)
as amended by the Health Information Technology for Economic and Clinical Health Act (the &ldquo;<B>HITECH Act</B>&rdquo;) (collectively,
the &ldquo;<B>Privacy Laws</B>&rdquo;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place,
comply in all material respects with, and take appropriate steps reasonably designed to ensure compliance in all material respects
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling,
and analysis of Personal Data (the &ldquo;<B>Policies</B>&rdquo;). &ldquo;<B>Personal Data</B>&rdquo; means (i)&nbsp;a natural
person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification
number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any
information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as
amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; and (iv)&nbsp;any other piece of information that allows
the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to
an identified person&rsquo;s health or sexual orientation. Except as could not reasonably be expected to have a Material Adverse
Effect or as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company and its subsidiaries
have at all times made all disclosures to users or customers required by applicable laws and regulatory rules&nbsp;or requirements,
and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation
of any applicable laws and regulatory rules&nbsp;or requirements. Except as could not reasonably be expected, individually or
in the aggregate, to have a Material Adverse Effect, neither the Company nor any of its subsidiaries: (i)&nbsp;has received notice
of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has
no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy
Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Complaints</I>. There is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against
the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&rsquo;s use
of the products or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services
and any office contained therein (&ldquo;<B>HHS</B>&rdquo;), or any similar authority in any jurisdiction other than the Unites
States or any other governmental entity, or by any person in respect of the collection, use or disclosure of Personal Data by
the Company or its subsidiaries, except as would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened,
except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of its significant
subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its
significant subsidiaries on the other, that is required by the Securities Act to be described in the Registration Statement and
the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Investment
Company Act</I>. The Company is not, and after giving effect to the issuance and sale of the Shares by the Company pursuant to
this Agreement and the application of the proceeds thereof received by the Company as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, will not be required to register as an &ldquo;investment company&rdquo; or
an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of
1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;<B>Investment Company
Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes.
</I>The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required
to be paid or filed through the date hereof except for taxes being contested in good faith and for which reserves in accordance
with GAAP have been taken; and except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the
Company or any of its subsidiaries or any of their respective properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(aa)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Licenses
and Permits. </I>The Company and its subsidiaries possess all licenses, certificates, permits and other authorizations issued
by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess
or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice
of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that
any such license, certificate, permit or authorization will not be renewed in the ordinary course, except in each case as would
not reasonably be expected to have a Material Adverse Effect. To the Company&rsquo;s knowledge, no party granting any such licenses,
certificates, permits and other authorizations has taken any action to limit, suspend or revoke the same in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(bb)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Labor Disputes. </I>No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to
the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance
by, or dispute with, the employees of any of its or its subsidiaries&rsquo; principal suppliers, contractors or customers, except
as would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(cc)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance
with and Liability under Environmental Laws.</I> (i)&nbsp;The Company and its subsidiaries (a)&nbsp;are, and since the Company&rsquo;s
inception were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements,
decisions, judgments, decrees, orders and the common law relating to pollution or the protection of the environment, natural resources
or human health or safety, including those relating to the generation, storage, treatment, use, handling, transportation, Release
or threat of Release of Hazardous Materials (collectively, &ldquo;<B>Environmental Laws</B>&rdquo;), (b)&nbsp;have received and
are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable
Environmental Laws to conduct their respective businesses, (c)&nbsp;have not received notice of any actual or potential liability
under or relating to, or actual or potential violation of, any Environmental Laws, including for the investigation or remediation
of any Release or threat of Release of Hazardous Materials, and have no knowledge of any event or condition that would reasonably
be expected to result in any such notice, (d)&nbsp;are not conducting or paying for, in whole or in part, any investigation, remediation
or other corrective action pursuant to any Environmental Law at any location, and (e)&nbsp;are not a party to any order, decree
or agreement that imposes any obligation or liability under any Environmental Law, and (ii)&nbsp;there are no costs or liabilities
associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and
(ii)&nbsp;above, for any such matter, as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; and (iii)&nbsp;except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
(a)&nbsp;there are no proceedings that are pending or, to the knowledge of the Company, contemplated against the Company or any
of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding
which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (b)&nbsp;the Company and its subsidiaries
are not aware of any facts or issues regarding the Company&rsquo;s or its subsidiaries&rsquo; compliance with Environmental Laws,
or liabilities or other obligations under Environmental Laws, including the Release or threat of Release of Hazardous Materials,
that could reasonably be expected to have a Material Adverse Effect, and (c)&nbsp;none of the Company and its subsidiaries anticipates
material capital expenditures relating to any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(dd)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Hazardous
Materials</I>. There has been no storage, generation, transportation, use, handling, treatment, Release or threat of Release of
Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and
its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries
is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated
or leased by the Company or any of its subsidiaries or at, on, under or from any other property or facility, in violation of any
Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under
any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. &ldquo;<B>Hazardous Materials</B>&rdquo; means any material, chemical, substance,
waste, pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including
crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally
occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental
Law. &ldquo;<B>Release</B>&rdquo; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting,
escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into
from or through any building or structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ee)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance
with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income
Security Act of 1974, as amended (&ldquo;<B>ERISA</B>&rdquo;), for which the Company or any member of its &ldquo;Controlled Group&rdquo;
(defined as any organization which is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of
the Code) would have any liability and which is established or maintained by the Company for the benefit of its employees (each,
a &ldquo;<B>Plan</B>&rdquo;) has been maintained in compliance with its terms and the requirements of any applicable statutes,
orders, rules&nbsp;and regulations, including but not limited to ERISA and the Code, except for noncompliance that could not reasonably
be expected to result in material liability to the Company or its subsidiaries; (ii)&nbsp;no prohibited transaction, within the
meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan excluding transactions
effected pursuant to a statutory or administrative exemption that could reasonably be expected to result in a material liability
to the Company or its subsidiaries; (iii)&nbsp;for each Plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of
the Code or Section&nbsp;302 of ERISA, the minimum funding standard of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA,
as applicable, has been satisfied (without taking into account any waiver thereof or extension of any amortization period) and
is reasonably expected to be satisfied in the future (without taking into account any waiver thereof or extension of any amortization
period); (iv)&nbsp;to the extent applicable to a Plan, the fair market value of the assets of each Plan exceeds the present value
of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (v)&nbsp;no &ldquo;reportable
event&rdquo; (within the meaning of Section&nbsp;4043(c)&nbsp;of ERISA) has occurred or is reasonably expected to occur that either
has resulted, or could reasonably be expected to result, in material liability to the Company or its subsidiaries; (vi)&nbsp;neither
the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV
of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect
of a Plan (including a &ldquo;multiemployer plan&rdquo;, within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA); and (vii)&nbsp;there
is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty
Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan that could reasonably be
expected to result in material liability to the Company or its subsidiaries. None of the following events has occurred or is reasonably
likely to occur: (x)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the
Company or its subsidiaries in the current fiscal year of the Company and its subsidiaries compared to the amount of such contributions
made in the Company and its subsidiaries&rsquo; most recently completed fiscal year; or (y)&nbsp;a material increase in the Company
and its subsidiaries&rsquo; &ldquo;accumulated post-retirement benefit obligations&rdquo; (within the meaning of Statement of
Financial Accounting Standards 106) compared to the amount of such obligations in the Company and its subsidiaries&rsquo; most
recently completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ff)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure
Controls</I>. Except as disclosed in the Registration Statement, the Prospectus and the Pricing Disclosure Package, The Company
and its subsidiaries maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule&nbsp;13a-15(e)&nbsp;of
the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, including controls and procedures
designed to ensure that such information is accumulated and communicated to the Company&rsquo;s management as appropriate to allow
timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness
of their disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(gg)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Accounting
Controls. </I>The Company and its subsidiaries maintain effective systems of &ldquo;internal control over financial reporting&rdquo;
(as defined in Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that are designed to comply with the requirements of Rule&nbsp;13a-15(a)&nbsp;of
the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial
officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal
accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements
in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with
management&rsquo;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the
existing assets at reasonable intervals and appropriate action is taken with respect to any differences, except as disclosed in
the Registration Statement, the Prospectus and the Pricing Disclosure Package. Based on the Company&rsquo;s most recent evaluation
of its internal controls over financial reporting pursuant to Rule&nbsp;13a-15(c)&nbsp;of the Exchange Act, there are no material
weaknesses in the Company&rsquo;s internal controls, except as disclosed in the Registration Statement, the Prospectus and the
Pricing Disclosure Package. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls
over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&rsquo;s ability
to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company&rsquo;s internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(hh)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>eXtensible
Business Reporting Language</I>. The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in
all material respects and has been prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Insurance.
</I>The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses,
including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company
reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the
Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements
or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
at reasonable cost from similar insurers as may be necessary to continue its business except as could not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(jj)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Unlawful Payments. </I>Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or
any of its subsidiaries nor, to the knowledge of the Company, any agent or affiliate of the Company or any of its subsidiaries
(in their capacities as such) has (i)&nbsp;used any funds for any unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of
any direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee, including
of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity
for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated
or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended (&ldquo;<B>FCPA</B>&rdquo;), or any
applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery
or anti-corruption laws; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or
other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper
payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and
enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(kk)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance
with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been conducted at all times
in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign
Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company
or any of its subsidiaries conducts business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations
or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, the &ldquo;<B>Anti-Money
Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority
or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ll)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or employees, nor, to
the knowledge of the Company, any agent or affiliate of the Company or any of its subsidiaries (in their capacities as such) is
currently the subject or the target of any sanctions administered or enforced by the U.S. Government, (including, without limitation,
the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without
limitation, the designation as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations
Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;),
nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or
the target of Sanctions, including, without limitation, Crimea, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B>Sanctioned
Country</B>&rdquo;); and the Company will not, directly or indirectly, use the proceeds of the sale of the Shares hereunder, or
lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity
(i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation,
is the subject or the target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country
or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction,
whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries
have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with any
person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(mm)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement
or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution
on such subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company
or from transferring any of such subsidiary&rsquo;s properties or assets to the Company or any other subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(nn)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Broker&rsquo;s Fees. </I>Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding
with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries
or any Underwriter for a brokerage commission, finder&rsquo;s fee or like payment in connection with the issuance and sale of
the Shares by the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Registration Rights</I>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and which have been duly waived, no person has the right to require the Company or any of its subsidiaries to register any securities
for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and
sale of the Shares by the Company pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(pp)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Stabilization. </I>The Company has not taken, directly or indirectly, without giving effect to the activities of the Underwriters,
any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price
of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(qq)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Forward-Looking
Statements. </I>No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E
of the Exchange Act) included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(rr)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Statistical
and Market Data. </I>Nothing has come to the attention of the Company that has caused the Company to believe that the statistical
and market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and
the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ss)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Sarbanes-Oxley
Act</I>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or executive officers,
in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including Section&nbsp;402 related to loans
and Sections&nbsp;302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(tt)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Status
under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the
earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under
the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; and
is a well-known seasoned issuer, in each case as defined in Rule&nbsp;405 under the Securities Act. The Company has paid the registration
fee for this offering pursuant to Rule&nbsp;456(b)(1)&nbsp;under the Securities Act or will pay such fee within the time period
required by such rule&nbsp;(without giving effect to the proviso therein) and in any event prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(uu)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Accuracy
of Disclosure</I>. The statements set forth in the Registration Statement, under the caption &ldquo;Description of Securities&ndash;Common
Stock,&rdquo; as supplemented and updated by the discussion set forth in the Prospectus under the heading &ldquo;Description of
Common Stock,&rdquo; and the statements set forth in the Prospectus under the heading &ldquo;Certain Material U.S. Federal Income
Tax and Estate Tax Consequences to Non-U.S. Holders,&rdquo; insofar as they purport to summarize the provisions of the laws and
documents referred to therein, are accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(vv)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Margin
Rules</I>. Neither the issuance, sale and delivery of the Shares by the Company nor the application of the proceeds thereof by
the Company as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation
T, U or X of the Board of Governors of the Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Further
Agreements of the Company</U>. The Company covenants and agrees with
each Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Required
Filings. </I>The Company will file the final Prospectus with the Commission within the time periods specified by Rule&nbsp;424(b)&nbsp;and
Rule&nbsp;430B under the Securities Act; will file any Issuer Free Writing Prospectus to the extent required by Rule&nbsp;433
under the Securities Act; will file promptly all reports and any definitive proxy or information statements required to be filed
by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act subsequent to the
date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of
the Shares; and will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered)
to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of
this Agreement in such quantities as the Representatives may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery
of Copies. </I>The Company will deliver, without charge, (i)&nbsp;to the Representatives, three signed copies of the Registration
Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and
documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement
as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined
below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference
therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &ldquo;<B>Prospectus
Delivery Period</B>&rdquo; means such period of time after the first date of the public offering of the Shares pursuant to this
Agreement as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered
(or required to be delivered but for Rule&nbsp;172 under the Securities Act) in connection with sales of the Shares by any Underwriter
or dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments
or Supplements,&nbsp;Issuer Free Writing Prospectuses. </I>Before preparing, using, authorizing, approving, referring to or filing
any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the Prospectus,
the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus,
amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any such Issuer Free Writing
Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice
to the Representatives. </I>The Company will advise the Representatives promptly, and confirm such advice in writing (which may
be by electronic mail), (i)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (ii)&nbsp;when
any supplement to the Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed;
(iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to
the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request
by the Commission for any additional information; (iv)&nbsp;of the issuance by the Commission of any order suspending the effectiveness
of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or the initiation or threatening of any proceeding, if the Company gains knowledge of such proceeding,
for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (v)&nbsp;of the occurrence of any event or development
within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free Writing
Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing
when the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not
misleading; (vi)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the Registration
Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act; and (vii)&nbsp;of
the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale
in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable
best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing
or suspending the use of any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus or suspending any such qualification
of the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall
exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary
to amend or supplement the Prospectus to comply with law, the Company will immediately notify the Underwriters thereof and forthwith
prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers
as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission
and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented
(or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances
existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if
at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which
the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the
Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the
Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriters thereof and forthwith prepare
and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and
to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any
document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in
the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing
Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue
Sky Compliance. </I>The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions
as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution
of the Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity
or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any
general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction
if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Earning
Statement. </I>The Company will make generally available to its security holders and the Representatives as soon as practicable
an earnings statement that satisfies the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158 of the
Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company
occurring after the &ldquo;effective date&rdquo; (as defined in Rule&nbsp;158) of the Registration Statement; <U>provided</U>
the Company will be deemed to have furnished such earning statement to its security holders and the Representatives to the extent
it is filed on the Commission&rsquo;s Electronic Data Gathering, Analysis, and Retrieval system (&ldquo;<B>EDGAR</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Clear
Market. </I>For a period of 60 days after the date of the Prospectus, the Company will not (i)&nbsp;offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, or file with the
Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into
or exercisable or exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing,
or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to
be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives,
other than (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Common Stock of the Company issued upon the exercise,
vesting or settlement of options, restricted stock units, stock appreciation rights or other awards granted under or covered by
the Company Stock Plans, (C)&nbsp;any shares of Common Stock of the Company issued upon the exercise of warrants outstanding on
the date of the Prospectus, as described in the Registration Statement, Pricing Disclosure Package and the Prospectus, (D)&nbsp;sales
of securities of the Company pursuant to the Company&rsquo;s employee stock purchase plan and grants of equity awards under the
Company Stock Plans, in each case as described in the Registration Statement, Pricing Disclosure Package and Prospectus, (E)&nbsp;the
filing of a registration statement on Form&nbsp;S-8 as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, (F)&nbsp;the issuance of shares of Stock or other securities (including securities convertible into shares
of Stock) in connection with the acquisition by the Company or any of its subsidiaries of the securities, businesses, properties
or other assets of another person or entity or pursuant to any employee benefit plan assumed by the Company in connection with
any such acquisition, or (G)&nbsp;the issuance of shares of Stock or other securities (including securities convertible into shares
of Stock) pursuant to equipment leasing arrangements or debt financing; <U>provided</U> that, in the case of clauses (F)&nbsp;and
(G), it being understood that any recipient shall enter into a lock-up letter with the Representatives in the form contemplated
by Exhibit&nbsp;A; <U>provided</U> that in the case of clause (G)&nbsp;no filings are required to be made under Section&nbsp;16(a)&nbsp;of
the Exchange Act in connection with such issuance; <U>provided</U> further that, in the case of clauses (F)&nbsp;and (G), taken
together, no more than 5.0% of the total outstanding shares of Stock as of the Closing Date are transferred, in the aggregate,
during the 60-day restricted period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Stabilization. </I>The Company will not take, directly or indirectly, without giving effect to the activities taken by the Underwriters,
any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price
of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Use
of Proceeds</I>. The Company will apply the net proceeds from the sale of the Shares pursuant to this Agreement as described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange
Listing</I>. The Company will use commercially reasonable efforts to list the Stock on the Nasdaq. The Company will use commercially
reasonable efforts to maintain such listing of the Stock on the Nasdaq for so long as the Securities are outstanding and the Company&rsquo;s
Common Stock is listed on the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Reports.
</I>For a period of two years from the date of this Agreement, the Company will furnish to the Representatives, promptly after
the date they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares,
and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange
or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements
to the Representatives to the extent they are filed on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Record
Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free
Writing Prospectus that is not filed with the Commission in accordance with Rule&nbsp;433 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Filings.
</I>The Company will file with the Commission such reports as may be required by Rule&nbsp;463 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain
Agreements of the Underwriters</U>. Each Underwriter hereby represents and
agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer
to or participate in the planning for use of, any &ldquo;free writing prospectus&rdquo;, as defined in Rule&nbsp;405 under the
Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated
by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus
that contains no &ldquo;issuer information&rdquo; (as defined in Rule&nbsp;433(h)(2)&nbsp;under the Securities Act) that was not
included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing
Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c)&nbsp;or Section&nbsp;4(c)&nbsp;above
(including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the
Company in advance in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final
terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided
</U>that Underwriters may use a term sheet substantially in the form of Annex B hereto without the consent of the Company; <U>provided</U><I>,
</I><U>further</U>, that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet
to the Company, prior to, or substantially concurrently with, the first use of such term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering contemplated
by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery
Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conditions
of Underwriters&rsquo; Obligations</U>. The obligation of each Underwriter to
purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be,
as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following
additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration
Compliance; No Stop Order. </I>No order suspending the effectiveness of the Registration Statement shall be in effect, and no
proceeding for such purpose pursuant to Rule&nbsp;401(g)(2)&nbsp;or pursuant to Section&nbsp;8A under the Securities Act shall
be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely
filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by
Rule&nbsp;433 under the Securities Act) and in accordance with Section&nbsp;4(a)&nbsp;hereof; and all requests by the Commission
for additional information shall have been complied with to the reasonable satisfaction of the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations
and Warranties. </I>The respective representations and warranties of the Company contained herein shall be true and correct on
the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the
Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of
the Closing Date or the Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Downgrade. </I>Subsequent to the earlier of (A)&nbsp;the Applicable Time and (B)&nbsp;the execution and delivery of this Agreement,
if there are any debt securities or preferred stock of, or guaranteed by, the Company or any of its subsidiaries that are rated
by a &ldquo;nationally recognized statistical rating organization,&rdquo; as such term is defined in Section&nbsp;3(a)(62) of
the Exchange Act, (i)&nbsp;no downgrading shall have occurred in the rating accorded any such debt securities or preferred stock
and (ii)&nbsp;no such organization shall have publicly announced that it has under surveillance or review, or has changed its
outlook with respect to, its rating of any such debt securities or preferred stock (other than an announcement with positive implications
of a possible upgrading).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Material Adverse Change. </I>No event or condition of a type described in Section&nbsp;3(g)&nbsp;hereof shall have occurred or
shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement
thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives
makes it impracticable or inadvisable to proceed with the issuance, offering, sale or delivery of the Shares on the Closing Date
or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing
Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Officers&rsquo;
Certificate. </I>The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the
case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior
executive officer of the Company who is reasonably satisfactory to the Representatives (i)&nbsp;confirming that such officers
have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of
such officers, the representations of the Company set forth in Sections&nbsp;3(b)&nbsp;and 3(d)&nbsp;hereof are true and correct,
(ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that
the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at
or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs
(a), (c)&nbsp;and (d)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Chief
Financial Officer&rsquo;s Certificate</I>. The Representatives shall have received a certificate, dated such Closing Date, of
the Chief Financial Officer of the Company, in form and substance satisfactory to the Representatives, substantially to the effect
set forth in Exhibit&nbsp;E attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort
Letters. </I>On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, each of
PricewaterhouseCoopers LLP and BDO USA, LLP shall have furnished to the Representatives, at the request of the Company, letters,
dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory
to the Representatives, containing statements and information of the type customarily included in accountants&rsquo; &ldquo;comfort
letters&rdquo; to underwriters with respect to the financial statements and certain financial information included or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; <U>provided</U>, that the letter
delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a &ldquo;cut-off&rdquo; date no more
than three business days prior to such Closing Date or such Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
and Negative Assurance Letter of Counsel for the Company. </I>Willkie Farr&nbsp;&amp; Gallagher LLP, counsel for the Company,
shall have furnished to the Representatives, at the request of the Company, their written opinion and negative assurance letter,
dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance
reasonably satisfactory to the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion
and Negative Assurance Letter of Counsel for the Underwriters. </I>The Representatives shall have received on and as of the Closing
Date or the Additional Closing Date, as the case may be, an opinion and negative assurance letter of Latham&nbsp;&amp; Watkins
LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel
shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Legal Impediment to Issuance and/or Sale. </I>No action shall have been taken and no statute, rule, regulation or order shall
have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the
Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company pursuant
to this Agreement; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of
the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company
pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Good
Standing</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case
may be, satisfactory evidence of the good standing of the Company and WageWorks,&nbsp;Inc. in their respective jurisdictions of
organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request,
in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange
Listing. </I>The Shares to be delivered on the Closing Date or Additional Closing Date, as the case may be, shall have been approved
for listing on the Nasdaq, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Lock-up
Agreements</I>. The &ldquo;lock-up&rdquo; agreements, each substantially in the form of Exhibit&nbsp;A hereto, between you and
each of the individuals and entities set forth on Annex C, relating to sales and certain other dispositions of shares of Stock
or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date
or Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional
Documents. </I>On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished
to the Representatives such further certificates and documents as the Representatives may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and
evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if
they are in form and substance reasonably satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnification
and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of the Underwriters by the Company. </I>The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors
and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act
or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without
limitation, reasonable and documented legal fees and other reasonable and documented expenses incurred in connection with any
suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of,
or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact included or incorporated by reference
in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated
therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue
statement of a material fact included or incorporated by reference in the Prospectus (or any amendment or supplement thereto),
any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under
the Securities Act, any road show as defined in Rule&nbsp;433(h)&nbsp;under the Securities Act (a &ldquo;road show&rdquo;) or
any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any
omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such
losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement
or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company
in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the
only such information furnished by any Underwriter consists of the information described as such in subsection&nbsp;(b)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification
of the Company. </I>Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above,
but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement
or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any road show or any Pricing
Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed
upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished
on behalf of each Underwriter: the information contained in the Prospectus under the caption &ldquo;Underwriting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice
and Procedures. </I>If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs
of this Section&nbsp;7, such person (the &ldquo;<B>Indemnified Person</B>&rdquo;) shall promptly notify the person against whom
such indemnification may be sought (the &ldquo;<B>Indemnifying Person</B>&rdquo;) in writing; <U>provided</U> that the failure
to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this
Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses)
by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it
from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7.
If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying
Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not,
without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person in such
proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding,
any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed
to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory
to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses
available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties
in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation
of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them. It is understood
and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons,
and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter,
its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives
and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control
persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement
of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason
of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested
that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph,
the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such
settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying
Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement.
No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened
proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought
hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person,
in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act
by or on behalf of any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Contribution.
</I>If the indemnification provided for in paragraphs (a), (b)&nbsp;and (c)&nbsp;above is unavailable to an Indemnified Person
or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under
such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by
such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering
of the Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the
relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions
that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative
benefits received by the Company, on the one hand, and the Underwriters on the other, in connection with the offering of the Shares
pursuant to this Agreement shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses)
received by the Company from the sale of the Shares pursuant to this Agreement and the total underwriting discounts and commissions
received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear
to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the
other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters
and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such statement
or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitation
on Liability. </I>The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to paragraph
(d)&nbsp;above were determined by <U>pro rata</U> allocation (even if the Underwriters were treated as one entity for such purpose)
or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (e)&nbsp;above.
The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in
paragraph (e)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred
by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and
(e)&nbsp;of this Section&nbsp;7, in no event shall an Underwriter be required to contribute any amount in excess of the amount
by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares
pursuant to this Agreement exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason
of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within
the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e)&nbsp;of
this Section&nbsp;7 are several in proportion to their respective purchase obligations hereunder and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Non-Exclusive
Remedies. </I>The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which
may otherwise be available to any Indemnified Person at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effectiveness
of Agreement</U>. This Agreement shall become effective
upon the execution and delivery hereof by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>. This Agreement may be terminated in the
absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and
prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date: (i)&nbsp;trading generally
shall have been suspended or materially limited on or by any of the New York Stock Exchange, or the Nasdaq; (ii)&nbsp;trading
of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market;
(iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities;
(iv)&nbsp;there shall have occurred any major disruption of settlements of securities, payment or clearance services in the United
States or any other country where such securities are listed; or (v)&nbsp;there shall have occurred any outbreak or escalation
of hostilities or declaration by the United States of a national emergency or war or any change in financial markets or any calamity
or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and
makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the
Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Defaulting
Underwriter</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase
the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange
for the purchase of such Shares by other persons satisfactory to the Company on the terms contained in this Agreement. If, within
36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares,
then the Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting
Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting
Underwriter, either the non-defaulting Underwriters or the Company may postpone the Closing Date or the Additional Closing Date,
as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company
or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or
arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus
that effects any such changes. As used in this Agreement, the term &ldquo;<B>Underwriter</B>&rdquo; includes, for all purposes
of this Agreement unless the context otherwise requires, any person not listed in Schedule&nbsp;1 hereto that, pursuant to this
Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on
the Closing Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares
to be purchased on such date, then the Company shall have the right to require each non-defaulting Underwriter to purchase the
number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&rsquo;s pro rata share
(based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter
or Underwriters for which such arrangements have not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting
Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on
the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to
be purchased on such date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement
or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing
Date shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant
to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will continue to be liable
for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall
not terminate and shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter
for damages caused by its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Payment
of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or
cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation,
(i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes payable
in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration
Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including
all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&rsquo;s
counsel and independent accountants; (iv)&nbsp;the fees and expenses incurred in connection with the registration or qualification
of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representatives may designate
and the preparation, printing and distribution of a Blue Sky Memorandum and any &ldquo;Canadian wrapper&rdquo; (including the
related fees and expenses of counsel for the Underwriters not to exceed an aggregate of $10,000); (v)&nbsp;the cost of preparing
stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application
fees incurred in connection with any filing with, and clearance of the offering by, FINRA (including the fees and expenses of
counsel for the Underwriters not to exceed an aggregate of $25,000); (viii)&nbsp;all expenses and application fees related to
the listing of the Stock on the Nasdaq; and (ix)&nbsp;all expenses incurred by the Company in connection with any &ldquo;road
show&rdquo; presentation to potential investors. Except as provided for by this Agreement, the Underwriters will pay all of their
own expenses, including the fees of their counsel and travel and lodging expenses of the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
(i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9, (ii)&nbsp;the Company for any reason fails to tender the Shares
for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under
this Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees
and expenses of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Persons
Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit
of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons
referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any
legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser
of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Survival</U>. The respective indemnities, rights of
contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made
by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of
this Agreement or any investigation made by or on behalf of the Company or the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except
where otherwise expressly provided, the term &ldquo;affiliate&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities
Act; (b)&nbsp;the term &ldquo;business day&rdquo; means any day other than a day on which banks are permitted or required to be
closed in New York City; and (c)&nbsp;the term &ldquo;subsidiary&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices.
</I>All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or
transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives
c/o (i)&nbsp;Wells Fargo Securities, LLC, 500 West 33<SUP>rd</SUP> Street, New York, New York 10001, Attention Equity Syndicate
Department (fax: (212) 214-5918); and (ii)&nbsp;J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax:
(212) 622-8358); Attention Equity Syndicate Desk. Notices to the Company shall be given to it at HealthEquity,&nbsp;Inc., 15 West
Scenic Pointe Drive, Draper, Utah 84020, (fax: (801) 727-1005), Attention: Delano Ladd, Executive Vice President, General Counsel
and Corporate Secretary, with a copy to (which shall not constitute notice): Willkie Farr&nbsp;&amp; Gallagher LLP, 787 Seventh
Avenue, New York, N.Y. 10019 (fax: (212) 728-8111), Attention: Matthew Haddad,&nbsp;Esq. and Jeffrey S. Hochman,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Governing
Law. </I>This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>USA
Patriot Act</I>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Underwriters are required to obtain, verify and record information that identifies the Underwriters&rsquo; respective
clients, including the Company, which information may include the name and address of the Underwriters&rsquo; respective clients,
as well as other information that will allow the Underwriters to properly identify the Underwriters&rsquo; respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Recognition
of the U.S. Special Resolution Regimes</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective
to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are
permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime
if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B><I>BHC Act Affiliate</I></B>&rdquo; has the
meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B><I>Covered Entity</I></B>&rdquo; means any
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)&nbsp;a &ldquo;covered entity&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii)&nbsp;a &ldquo;covered bank&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(iii)&nbsp;a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B><I>Default Right</I></B>&rdquo; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&ldquo;<B><I>U.S. Special Resolution Regime</I></B>&rdquo;
means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of
the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Waiver
of Jury Trial</I>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts.
</I>This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication),
each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be
delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments
or Waivers. </I>No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom,
shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings.
</I>The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning
or interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Integration.
</I>This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters,
or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature pages&nbsp;follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with
your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">HEALTHEQUITY,&nbsp;INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">/s/ Jon Kessler</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 45%">Jon Kessler</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Accepted: As of the date first written above</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">WELLS FARGO SECURITIES, LLC</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">For itself and on behalf of the several</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Underwriters listed in Schedule&nbsp;1 hereto.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt; width: 45%">/s/ Geoffrey Goodman</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">J.P. MORGAN SECURITIES LLC</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">For itself and on behalf of the several</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Underwriters listed in Schedule&nbsp;1 hereto.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt">/s/ Tommy Reuger</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">Tommy Reuger</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Managing Director </TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;to Underwriting
Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule&nbsp;1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">Wells Fargo Securities, LLC</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,840,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">J.P. Morgan Securities LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">920,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Goldman Sachs&nbsp;&amp; Co. LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">460,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">RBC Capital Markets, LLC</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">460,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">BofA Securities,&nbsp;Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">230,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Citizens Capital Markets,&nbsp;Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">230,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Deutsche Bank Securities Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">230,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Raymond James&nbsp;&amp; Associates,&nbsp;Inc.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">230,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,600,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>a.</B></TD><TD STYLE="text-align: justify"><B>Pricing Disclosure Package</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>b.</B></TD><TD STYLE="text-align: justify"><B>Pricing Information Provided Orally by Underwriters</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%">Public offering price:</TD>
    <TD STYLE="width: 71%">$56.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Common Stock offered:</TD>
    <TD>4,600,000 shares of Common Stock, plus up to 690,000 shares of Common Stock issuable upon the exercise of the Underwriters&rsquo; option to purchase additional shares</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HealthEquity,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pricing Term Sheet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lock-up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward Bloomberg</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank A. Corvino</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian T. Dillon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evelyn Dilsaver</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Angelique Hill</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Hostetter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jon Kessler</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delano Ladd</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debra McCowan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darcy Mott</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen D. Neeleman, M.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Robert Otten</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Sacks</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert W. Selander</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Larry Trittschuh</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gayle Wellborn</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit&nbsp;A</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Lock-up Agreement</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WELLS FARGO SECURITIES, LLC<BR>
500 West 33<SUP>rd</SUP> Street<BR>
New York, New York 10001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. MORGAN SECURITIES LLC<BR>
383 Madison Avenue<BR>
New York, New York 10179</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>HealthEquity,&nbsp;Inc.
 &mdash; Public Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that you propose
to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) between HealthEquity,&nbsp;Inc., a Delaware
corporation (the &ldquo;<B>Company</B>&rdquo;) and Wells Fargo Securities, LLC and J.P. Morgan Securities LLC, as representatives
(the &ldquo;<B>Representatives</B>&rdquo;) for the several underwriters listed in Schedule&nbsp;1 thereto (the &ldquo;<B>Underwriters</B>&rdquo;),
providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of common stock (the &ldquo;<B>Common Stock</B>&rdquo;),
$0.0001 per share par value, of the Company (the &ldquo;<B>Securities</B>&rdquo;). Capitalized terms used herein and not otherwise
defined shall have the meanings set forth in the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration of the Representatives&rsquo;
agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt of
which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives, the
undersigned will not, during the period commencing on the date hereof and ending 60 days (the &ldquo;<B>Lock-up Period</B>&rdquo;)
after the date of the final prospectus relating to the Public Offering (the &ldquo;<B>Prospectus</B>&rdquo;), (1)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities
which may be deemed to be beneficially owned by the undersigned in accordance with the rules&nbsp;and regulations of the Securities
and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), or publicly disclose the
intention to make any offer, sale, pledge or disposition, (2)&nbsp;enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction
described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash
or otherwise or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of Common Stock
or any security convertible into or exercisable or exchangeable for Common Stock (and for avoidance of doubt, the undersigned
hereby waives any and all notice requirements and rights with respect to the registration of any securities pursuant to any agreement,
instrument, understanding or otherwise, including any stockholders or registration rights agreement or similar agreement, to which
the undersigned is a party or under which the undersigned is entitled to any right or benefit), in each case other than (A)&nbsp;the
Securities to be sold by the undersigned pursuant to the Underwriting Agreement, if any, (B)&nbsp;transfers of shares of Common
Stock or such other securities as a bona fide gift or gifts, (C)&nbsp;transfers or dispositions of shares of Common Stock or such
other securities to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned
in a transaction not involving a disposition for value, (D)&nbsp;transfers or dispositions of shares of Common Stock or such other
securities to any of the undersigned&rsquo;s affiliates (as defined in Rule&nbsp;405 promulgated under the Securities Act of 1933,
as amended) or to any investment fund or other entity controlled or managed by the undersigned, (E)&nbsp;transfers or dispositions
of shares of Common Stock or such other securities by will, other testamentary document or intestate succession to the legal representative,
heir, beneficiary or a member of the immediate family of the undersigned, and (F)&nbsp;distributions of shares of Common Stock
or such other securities to partners, members or stockholders of the undersigned; <U>provided,</U> that in the case of any transfer,
disposition or distribution pursuant to clause (B), (C), (D), (E)&nbsp;or (F), each transferee, donee or distributee shall execute
and deliver to the Representatives a lock-up letter in the form of this letter agreement; and <U>provided</U>, <U>further</U>,
that in the case of any transfer, disposition or distribution pursuant to clause (B), (C), (D)&nbsp;or (F), no filing by any party
(donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;),
reporting a reduction in beneficial ownership or transfer or disposition of any rights in Common Stock held by the undersigned
or other public announcement shall be required or shall be made voluntarily in connection with such transfer, disposition or distribution
(other than a filing on a Form&nbsp;5 made after the expiration of the Lock-up Period). For purposes of this letter agreement,
 &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.
Furthermore, notwithstanding the restrictions imposed by this letter agreement, the undersigned may, without the prior written
consent of the Representatives, (i)&nbsp;exercise an option to purchase shares of Common Stock granted under any stock incentive
plan or stock purchase plan of the Company; <U>provided</U>, that any shares of Common Stock received by the undersigned upon
such exercise shall be subject to the restrictions on transfer set forth in this letter agreement, and <U>provided</U>, <U>further</U>,
that no filing under Section&nbsp;16(a)&nbsp;of the Exchange Act or other public announcement shall be required or shall be voluntarily
made within 30 days after the date of the Prospectus, and after such 30th day, any filing under the Exchange Act shall clearly
indicate in the footnotes thereto that (a)&nbsp;the filing relates to the circumstances described in this clause (i), (b)&nbsp;no
shares were sold by the reporting person and (c)&nbsp;the shares received upon exercise of the option are subject to a lock-up
agreement with the Representatives; (ii)&nbsp;exercise warrants to purchase shares of Common Stock or any security convertible
into or exercisable or exchangeable for Common Stock; <U>provided</U>, that any shares of Common Stock received by the undersigned
upon such exercise shall be subject to the restrictions set forth in this letter agreement, (iii)&nbsp;transfer the undersigned&rsquo;s
Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company pursuant to any contractual
arrangement in effect on the date of this letter agreement that provides for the repurchase of the undersigned&rsquo;s Common
Stock or such other securities by the Company or in connection with the termination of the undersigned&rsquo;s employment with
the Company, <U>provided</U> that no filing under the Exchange Act or other public announcement shall be required or voluntarily
made by the undersigned or any other person in connection therewith, in each case during the Lock-up Period, (iv)&nbsp;transfer
the undersigned&rsquo;s Common Stock or any security convertible into or exercisable or exchangeable for Common Stock to the Company
in connection with a vesting event of the Company&rsquo;s securities or upon the exercise of warrants or options to purchase the
Company&rsquo;s securities, on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis or to cover tax withholding obligations
of the undersigned in connection with such vesting or exercise, <U>provided</U> that the underlying shares shall continue to be
subject to the restrictions on transfer set forth in this letter agreement, (v)&nbsp;establish a trading plan pursuant to Rule&nbsp;10b5-1
under the Exchange Act (&ldquo;<B>Rule&nbsp;10b5-1</B>&rdquo;) for the transfer of Common Stock; <U>provided</U>, that such plan
does not provide for any transfers of Common Stock, and no filing with the Securities and Exchange Commission or other public
announcement shall be required or voluntarily made by the undersigned or any other person in connection therewith, in each case
during the Lock-up Period, (vi)&nbsp;transfer or dispose of Securities acquired on the open market following the Public Offering;
<U>provided</U> that no filing by any party under the Exchange Act reporting a reduction in beneficial ownership or transfer or
disposition of any rights in Common Stock held by the undersigned or other public announcement shall be required or shall be made
voluntarily in connection with such transfer or disposition (other than a filing on a Form&nbsp;5 made after the expiration of
the Lock-up Period), and (vii)&nbsp;execute sales of Common Stock made pursuant to a trading plan pursuant to Rule&nbsp;10b5-1
that has been entered into by the undersigned prior to the date of this letter agreement; <U>provided</U>, that to the extent
a public announcement or filing under the Exchange Act, if any, is required or voluntarily made by or on behalf of the undersigned
or the Company regarding any such sales, such announcement or filing shall include a statement to the effect that the sale was
made pursuant to a trading plan pursuant to Rule&nbsp;10b5-1. Notwithstanding the foregoing, the undersigned shall be permitted
to make required filings on a Schedule&nbsp;13D, Schedule&nbsp;13F or Schedule&nbsp;13G under the Exchange Act, provided that
any such filings shall not be made in connection with a transfer, disposition or distribution of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The restrictions contained herein shall
not apply to any transfers, sales, tenders or other dispositions of Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock pursuant to a bona fide third party tender offer, merger, amalgamation, consolidation or other
similar transaction made to or involving all holders of the Common Stock or such other securities pursuant to which one hundred
percent (100%) ownership of the Company is transferred to such third party (including, without limitation, the entering into any
lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose
of Common Stock or other such securities in connection with such transaction, or vote any Common Stock or other such securities
in favor of any such transaction); <U>provided</U>, that if such tender offer merger, amalgamation, consolidation or other similar
transaction is not completed, any Common Stock or any security convertible into or exercisable or exchangeable for Common Stock
subject to this letter agreement shall remain subject to the restrictions contained in this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In furtherance of the foregoing, the Company,
and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized
to decline to make any transfer of securities if such transfer would constitute a violation or breach of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby represents and warrants
that the undersigned has full power and authority to enter into this letter agreement. All authority herein conferred or agreed
to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives
of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned hereby waives any and all
notice requirements and rights with respect to the registration of securities pursuant to any agreement, instrument, understanding
or otherwise, including any stockholders or registration rights agreement or similar agreement, to which the undersigned is a party
or under which the undersigned is entitled to any right or benefit, <U>provided</U>, however, that such waiver shall apply only
to the proposed Public Offering, and any other action taken by the Company in connection with the proposed Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned acknowledges and agrees
that the underwriters have not provided any recommendation or investment advice nor have the underwriters solicited any action
from the undersigned with respect to the offering of the securities and the undersigned has consulted their own legal, accounting,
financial, regulatory and tax advisors to the extent deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned understands that, if (i)&nbsp;the
Representatives, on the one hand, or the Company, on the other hand, inform the other in writing, prior to the execution of the
Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Underwriting Agreement does
not become effective by September&nbsp;8, 2020 (provided that the Company may by written notice to the undersigned extend such
date for a period of up to two additional months), (iii)&nbsp;the Underwriting Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder,
or (iv)&nbsp;the registration statement filed with the Securities and Exchange Commission in connection with the Public Offering
is withdrawn, the undersigned shall be released from all obligations under this letter agreement. The undersigned understands that
the Company and the Representatives are relying upon this letter agreement in proceeding toward consummation of the Public Offering.
Whether or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering
will only be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and
the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This letter agreement and any claim, controversy
or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with the laws of
the State of New York, without regard to the conflict of laws principles thereof.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Security Holder <I>(Print exact name)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If not signing in an individual capacity:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Authorized Signatory <I>(Print)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Authorized Signatory <I>(Print)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Chief Financial Officer&rsquo;s
Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>hqy-20200708.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K85w7xRiXgen8uNbXAsWayJabPtzp5xiekhuWh3bbkqfyQt5q+qhCkn2LPWoeoE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:hqy="http://healthequity.com/20200708" elementFormDefault="qualified" targetNamespace="http://healthequity.com/20200708">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://healthequity.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20200708_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hqy-20200708_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>hqy-20200708_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>hqy-20200708_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://healthequity.com/role/Cover" xlink:href="hqy-20200708.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://healthequity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>tm2024096d4_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hqy-20200708.xsd" xlink:type="simple"/>
    <context id="From2020-07-08to2020-07-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001428336</identifier>
        </entity>
        <period>
            <startDate>2020-07-08</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-07-08to2020-07-08">0001428336</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-07-08to2020-07-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-07-08to2020-07-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-07-08to2020-07-08">2020-07-08</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2020-07-08to2020-07-08">001-36568</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-07-08to2020-07-08">HEALTHEQUITY,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-07-08to2020-07-08">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-07-08to2020-07-08">001-36568</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-07-08to2020-07-08">52-2383166</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-07-08to2020-07-08">15 West Scenic Pointe Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-07-08to2020-07-08">Suite&#160;100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-07-08to2020-07-08">Draper</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-07-08to2020-07-08">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-07-08to2020-07-08">84020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-07-08to2020-07-08">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-07-08to2020-07-08">727-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2020-07-08to2020-07-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-07-08to2020-07-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-07-08to2020-07-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-07-08to2020-07-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-07-08to2020-07-08">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="From2020-07-08to2020-07-08">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-07-08to2020-07-08">HQY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-07-08to2020-07-08">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140441935512104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  08,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HEALTHEQUITY,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001428336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2383166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15 West Scenic Pointe Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Draper<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">727-1000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HQY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " ".9.E0!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( (YDZ5!/$*=G[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (YDZ5"97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MCF3I4,CO08-8!   WA   !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (YDZ5"#J:4#U $  #(&   -
M          "  9P,  !X;"]S='EL97,N>&UL4$L! A0#%     @ CF3I4)>*
MNQS     $P(   L              ( !FPX  %]R96QS+RYR96QS4$L! A0#
M%     @ CF3I4*K$(A8S 0  (@(   \              ( !A \  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( (YDZ5 D'INBK0   /@!   :
M      "  >00  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( (YDZ5!ED'F2&0$  ,\#   3              "  <D1  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  !,3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2024096d4_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://healthequity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2024096d4_8k.htm">tm2024096d4_8k.htm</File>
    <File>hqy-20200708.xsd</File>
    <File>hqy-20200708_lab.xml</File>
    <File>hqy-20200708_pre.xml</File>
    <File>tm2024096d4_ex1-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2024096d4_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2024096d4_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hqy-20200708_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hqy-20200708_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hqy-20200708.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hqy",
   "nsuri": "http://healthequity.com/20200708",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2024096d4_8k.htm",
      "contextRef": "From2020-07-08to2020-07-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://healthequity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2024096d4_8k.htm",
      "contextRef": "From2020-07-08to2020-07-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://healthequity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r11": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r13": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r14": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-20-082309-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-082309-xbrl.zip
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M!LAQC@SQ#TLQ[+KE=YR])#2"!]20W LV@&DK.YHV/(#L!OLHJH?+*LX_2M7
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M0E0H/5+P&=,GOGW.H_T=9Q$A\HVNK&Z_^N[:#8QV2\Z;BM1F:E!H0+2]Q2_
MX2$+U,CC0Z,/\W\+4+ZX+M>J8]'3XA&+TWB[S3/9LPI[\'WTSB#'#R@&%$![
M3-$1$1"  VQ"CRR*2%2$?D!E,&I$>[V&RPXK'9+X\_Z>/! N9T LR2[_+ [W
MU'$5,B#6]17>X.+H%WR]@4&@^%:WT.5@AIH9H)5\$ZW* OTN,T%%+K9OPS=W
M78LML5OM$K]6."-BSW\!4$L#!!0    ( (YDZ5"L_-K+6@<  #M9   4
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MUXYKTIFNXDF ))]9  VMQG1 N',IHQIGNO+(KD75E0==*;,+6F[C*3I4C\F
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MR(QXN;:;:[=^-+XIEOP?4$L#!!0    ( (YDZ5#P)E6O-YT  "%V P 5
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M)3O(BA(K#H:V.UF%;O5"K(9S3N2$4N@(["C4-A0#Y& _@0" 7,SUF:;6&=G
MFSCX!BM\%AT8E\V9[TTS[;\:7)Q=#JM,K,/>-\&S#_ASHU:2=+--7ZB8NTSQ
M59)WJ:K4.U>IIVY5%K(66\SM]S"[[&]P?P_MZ[SQ<9>P)U=[OY)&GQMF]KYU
M&29F^AMLJ5US?HRD*PFI_;VQBO@7H@*G)9EIS>JW *0Y^9#2,^7UJXU9N#^Q
MX7W%N!<;X4YFC4JL:%I@&6FUOW==XBK:7EK!M=JYN(JN(*T8$N8:Q%6TE;0:
M1$%V):ZT]U;:_R:5\O[>]<FL:"N1!3;I_U*9M;L,*LBL%VBC@1KX&4XE^E-8
MI&\9_AYF;:::*-E0FVR3#G/G05AK?\_&V@BHQSD'/8BLN)]#ZI4=X._RVD<0
MA0L.R2REREKIE(JI 3%&%)6SJL:^1(Q:K5 0<&-[D(2B!FF)5,@3Z 'F^W$D
MWW9?UCLJN2O-QB$F5U=B<!UYTK<G^2ZOK5%:I"$3;T2;MUU+45>M:*BXK !M
M^ K4B7242TS5?6;679KH/IP$V>5T<X*%]O/?$IR?/JGHP)Q4TGN8)2Y*O")!
MR7*0"V]SFQOZE2;QQ[P:3;!JT*9JWNR>:;MQZ1P=U1BUQK37!\@%@?"X!P[9
MP?'1H?/+1E%>D#C^ (_O/U@#*U3#"G6)E'YV#</<<$:YB[#C+&8OF=+&=04T
MC>HJP5A:=>&ZJID"HRS71([-C5[(*:Q*NF@\1W-W?^^Y8XWU9S'I=$6;?2[G
M/B)JGL07#QB<@"T;<K=6\#C0*#X9'UZ9^_</I=]ZHEIM !?"^A*D+7*'MUDX
M+LI1_+1BGX4X9P$WJC4I0*.#M@9OF1:FONF\KV+!;W>.+Z+I<5$CV"=8/7":
M\:GKJJ:D\7S.EYA )["%P14^NIQ8ZO.2L3WR25417\U*O7JNV1FIY+1\HI7:
M^\#5;5!7Z/-97>:A#<JQMT]RF;-M;S5\>YRCB!C78\I>S?%&"?$QINS';GS4
M-^<C^5R&[O:^^?;R6V%"4,%S;Z4MBJ+B[6[64%R_)7G<!"X$2?_,PGMR]2>&
MO%S%XQ#R!<^D;/."Z* %T?3BP67 FBH2^^@_\K\GBL0:ZQ+T2?3@(#TT<@L%
M/.=JK;EGT3SL":CE19H +4G]=^-45Z G6'M=FZ*X/G2+SYPL>_!E)<L>?$V6
MW:(".W"9)T!+26CT/>=WTQ<W)U=-@8T4RC-:A^1ID-W$4]0X5^@MCOLD)*^<
M=3T-VX8RK]>.@EKBDGH;!ST8^WNL71YKLL27NU;4F&BT@$4BJFPVB532! B@
MU)]@_\D= [*H2%"2P^#*V5%0C^.#T\.#>YL  QUA:C %\_-!O??=R.7'PHS8
M_MY(J\+DJ6^7'$,Z@C4X!P,"W\(%> D!(B)\&E5;3[JHWYU,,("69_:\>$5K
M'2F.,LK9+YQZ)QC3,B;(+OR4*_N*AG4G(*7 JQK;[&/C"R0^YCV*3#9!43&V
MUG"(ELS$Z\Y%'\*%S%-/<FZM,Q#H-Y=D65S1SR6/,D^']L;5G1NPJ]9Z-[L/
MP??=%SD%=YCVW-:A)7*"V6$9ZE7^" =R?V^S!]E;S=1I7CEHP?GL3SC #=[I
M]N='C+BC',K'NJ\XA.V/GSX]A_+1&5\BPF=V/*W_@QB*6SB>&Z31QUT==$@1
MK>%KYN5&%TUCYL4X?/M[SS3JZ^U&'PC^2-]P(/ \6ZV)*FJ7M%SW:3M1;MBZ
M(*]<(9%?<H>9=2S"9<SJHZQ*;PWZW:\OHUDC4-=6T7B5AR;,9Y24>I$5(]B
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MN@#Z%,=RFE)YV]OMJ[JBL27)!&FY$FI$7TP2F;CQ^JCL*Z#&I8POCY&I>"?
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M3-QGJIC"("6S'2'2;L75GC\#KHPE>G055+9;F&3;+CS^_9<5'O_^:WC\V@V
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MP:6V8NKW D2/$,@C?#997>&3-SSX4IWB!?;_*OZ#A_41WSC>#NO<C3/6_+
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M"NYKVFL6<VF*I0#LR\\BOB"7I'4EN**%>L^_;;=N=\AO>.O$ZS+M4Z0:!>_
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MY1620J)?0IOV<J(2/W(N"$^[W]^;H7@K=52YJ7_ S6PI*(<FX+;2,I2":ZW
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M(9+@I$WM+Y <EA."TQ9I'ZHY>&]0':N(&SW& X_B535]#N'@DHF1)6.&MU1
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MQK!0E^O(GJ9AH?GT 1:$Q:6FBMAR4-YUT(Q#WMVB<N\\-KKR=_4U<)YM]A8
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MR%(_Y,+A4I6NG,GYQ+NR4FSO:C7?>NYXJK.A#<%<UD%SZ9U]4;<H27!42A_
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M]+U--9<QPHF[("LR8JG!)/)RO4,\,&73* Y#!OH(NYQ7JG. U\E=\*(AT?,
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MFBN"R)5BR44*]IZ^5Q/,HA@1U-+]-Q'I:QI;"HU=XAW)FL@6!U $F:X!5#H
M 2S3X;6^&.@?\79@DF:Q%^!RU/?"ERVCS$1=-Y)-%VJ1\2OT<M[]W<+^N^NP
M_Y/->U[V+&RK@_7A,QV);?6E/KH._ $@75Y*8L@QZ/N)45^*LG= XFZAYZW=
MG@+#0F$[EVC:,_+"S]PT>W;BZ>_CYU>'7X[_12KJX^6G,_CA_P%02P$"% ,4
M    " ".9.E0"PH$)4D#  "8#   $               @ $     :'%Y+3(P
M,C P-S X+GAS9%!+ 0(4 Q0    ( (YDZ5 /5SN%_0H  -^'   4
M      "  7<#  !H<7DM,C R,# W,#A?;&%B+GAM;%!+ 0(4 Q0    ( (YD
MZ5"L_-K+6@<  #M9   4              "  :8.  !H<7DM,C R,# W,#A?
M<')E+GAM;%!+ 0(4 Q0    ( (YDZ5!KN3Z+-Q0   1P   2
M  "  3(6  !T;3(P,C0P.39D-%\X:RYH=&U02P$"% ,4    " ".9.E0\"95
MKS>=   A=@, %0              @ &9*@  =&TR,#(T,#DV9#1?97@Q+3$N
9:'1M4$L%!@     %  4 10$   /(      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
